177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation

被引：19
|
作者：
Assadi, Majid [1 ]
Pirayesh, Elahe [2 ]
Rekabpour, Seyed Javad [3 ]
Zohrabi, Farshad [4 ]
Jafari, Esmail [1 ]
Nabipour, Iraj [5 ]
Esmaili, Abdolhamid [6 ]
Amini, Abdullatif [7 ]
Ahmadzadehfar, Hojjat [8 ]
机构：
[1] Bushehr Univ Med Sci, Bushehr Med Univ Hosp, Persian Gulf Nucl Med Res Ctr, Dept Mol Imaging & Radionuclide Therapy,Fac Med, Bushehr, Iran
[2] Shahid Beheshti Univ Med Sci, Shohada & Tajrish Med Ctr, Dept Nucl Med, Tehran, Iran
[3] Bushehr Med Univ Hosp, Dept Oncol, Bushehr, Iran
[4] Bushehr Med Univ Hosp, Dept Urol, Bushehr, Iran
[5] Bushehr Med Univ Hosp, Dept Internal Med, Div Endocrinol, Bushehr, Iran
[6] Bushehr Med Univ Hosp, Dept Pathol, Bushehr, Iran
[7] Bushehr Univ Med Sci, Dept Cardiol, Bushehr Heart Med Ctr, Bushehr, Iran
[8] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany
来源：
CLINICAL NUCLEAR MEDICINE | 2019年 / 44卷 / 12期
关键词：
prostate cancer; neuroendocrine differentiation; Lu-177-PSMA; Lu-177-DOTATATE; GA-68-PSMA; MEDICINE;
D O I：
10.1097/RLU.0000000000002824
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
We presented a promising result of radionuclide therapy using Lu-177-PSMA and Lu-177-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer.
引用
收藏
页码：978 / 980
页数：3
相关论文
共 50 条
  • [21] Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer
    Andrei Gafita
    Hui Wang
    Robert Tauber
    Calogero D’Alessandria
    Wolfgang A. Weber
    Matthias Eiber
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 2212 - 2213
  • [22] Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer
    Gafita, Andrei
    Wang, Hui
    Tauber, Robert
    D'Alessandria, Calogero
    Weber, Wolfgang A.
    Eiber, Matthias
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (10) : 2212 - 2213
  • [23] Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy
    von Eyben, Finn Edler
    Kulkarni, Harshad R.
    Baum, Richard P.
    THERANOSTICS, 2020, 10 (11): : 4900 - 4902
  • [24] Systemic radioligand therapy with 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer
    Eiber, Matthias
    Heck, Matthias
    Tauber, Robert
    Rauscher, Isabel
    D'Alessandria, Calogero
    Maurer, Tobias
    Retz, Margitta
    Wester, Hans
    Schwaiger, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [25] Care Pathway at a Cancer Center for the Administration of Radiometabolic Therapy with 177Lu-PSMA in Patients with Metastatic Castration-resistant Prostate Cancer
    Avila, Carlos
    Cadavid, Tatiana
    Martinez, Maria Cristina
    Varela, Humberto
    Hernandez-Hidalgo, Nathalie
    MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, 2024, 33 (01) : 28 - 37
  • [26] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [27] PSA flare in patients with metastatic castration-resistant prostate cancer undergoing 177Lu-PSMA treatment.
    Li, Haoran
    Wulff-Burchfield, Elizabeth Marie
    Abbasi, Saqib
    Narang, Arshit
    Dal, Emre
    Donald, Joseph
    Yap, Wendell Y.
    Shen, Xinglei
    Chen, Ronald C.
    Parikh, Rahul Atul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 157 - 157
  • [28] 177Lu-PSMA With Olaparib Radiosensitization Potentiates Response and Toxicity in Extensive Castration-Resistant Metastatic Prostate cancer
    Kao, Yung Hsiang
    Falzone, Nadia
    Pearson, Michael
    Pook, David
    Sivaratnam, Dinesh
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (10) : 966 - 967
  • [29] Neuroendocrine Tumor Therapy: 177Lu-DOTATATE
    Mittra, Erik S.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2018, 211 (02) : 278 - 285
  • [30] Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
    Feuerecker, Benedikt
    Chantadisai, Maythinee
    Allmann, Anne
    Tauber, Robert
    Allmann, Jakob
    Steinhelfer, Lisa
    Rauscher, Isabel
    Wurzer, Alexander
    Wester, Hans-Juergen
    Weber, Wolfgang A.
    d'Alessandria, Calogero
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (06) : 833 - 839
12345